JP2020536518A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020536518A5 JP2020536518A5 JP2020517588A JP2020517588A JP2020536518A5 JP 2020536518 A5 JP2020536518 A5 JP 2020536518A5 JP 2020517588 A JP2020517588 A JP 2020517588A JP 2020517588 A JP2020517588 A JP 2020517588A JP 2020536518 A5 JP2020536518 A5 JP 2020536518A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- amino acid
- fusion protein
- acid residues
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000037865 fusion proteins Human genes 0.000 claims 22
- 108020001507 fusion proteins Proteins 0.000 claims 22
- 125000000539 amino acid group Chemical group 0.000 claims 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 108060003951 Immunoglobulin Proteins 0.000 claims 6
- 102000018358 immunoglobulin Human genes 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 102000004551 Interleukin-10 Receptors Human genes 0.000 claims 4
- 108010017550 Interleukin-10 Receptors Proteins 0.000 claims 4
- 239000013604 expression vector Substances 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 238000003776 cleavage reaction Methods 0.000 claims 3
- 230000002519 immonomodulatory effect Effects 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 230000007017 scission Effects 0.000 claims 3
- 230000004614 tumor growth Effects 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 102000003839 Human Proteins Human genes 0.000 claims 2
- 108090000144 Human Proteins Proteins 0.000 claims 2
- 102000003814 Interleukin-10 Human genes 0.000 claims 2
- 108090000174 Interleukin-10 Proteins 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 102000026898 cytokine binding proteins Human genes 0.000 claims 2
- 108091008470 cytokine binding proteins Proteins 0.000 claims 2
- 102000003675 cytokine receptors Human genes 0.000 claims 2
- 108010057085 cytokine receptors Proteins 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 230000012010 growth Effects 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000006337 proteolytic cleavage Effects 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 102000004961 Furin Human genes 0.000 claims 1
- 108090001126 Furin Proteins 0.000 claims 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 1
- 101001033233 Homo sapiens Interleukin-10 Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 201000000220 brain stem cancer Diseases 0.000 claims 1
- 239000005018 casein Substances 0.000 claims 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims 1
- 235000021240 caseins Nutrition 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 208000024519 eye neoplasm Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 1
- 201000003115 germ cell cancer Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 102000052620 human IL10 Human genes 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000016035 malignant germ cell tumor of ovary Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 201000008106 ocular cancer Diseases 0.000 claims 1
- -1 optionally Proteins 0.000 claims 1
- 201000008042 ovarian germ cell cancer Diseases 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000017854 proteolysis Effects 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023081001A JP7702445B2 (ja) | 2017-09-27 | 2023-05-16 | 免疫調節融合タンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762564145P | 2017-09-27 | 2017-09-27 | |
| US62/564,145 | 2017-09-27 | ||
| PCT/US2018/053197 WO2019067770A1 (en) | 2017-09-27 | 2018-09-27 | IMMUNOMODULATORY FUSION PROTEINS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023081001A Division JP7702445B2 (ja) | 2017-09-27 | 2023-05-16 | 免疫調節融合タンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020536518A JP2020536518A (ja) | 2020-12-17 |
| JP2020536518A5 true JP2020536518A5 (enExample) | 2021-10-21 |
Family
ID=65902489
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517588A Withdrawn JP2020536518A (ja) | 2017-09-27 | 2018-09-27 | 免疫調節融合タンパク質 |
| JP2023081001A Active JP7702445B2 (ja) | 2017-09-27 | 2023-05-16 | 免疫調節融合タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023081001A Active JP7702445B2 (ja) | 2017-09-27 | 2023-05-16 | 免疫調節融合タンパク質 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11834492B2 (enExample) |
| EP (1) | EP3688037A4 (enExample) |
| JP (2) | JP2020536518A (enExample) |
| KR (1) | KR102757384B1 (enExample) |
| CN (2) | CN111511769B (enExample) |
| AU (2) | AU2018338612A1 (enExample) |
| BR (1) | BR112020006115A2 (enExample) |
| CA (1) | CA3077223A1 (enExample) |
| EA (1) | EA202090838A1 (enExample) |
| IL (1) | IL273626B2 (enExample) |
| MX (1) | MX2020003672A (enExample) |
| SG (1) | SG11202002826VA (enExample) |
| WO (1) | WO2019067770A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3519442A4 (en) | 2016-09-27 | 2020-06-17 | EpicentRx, Inc. | Immunomodulatory fusion proteins |
| WO2021147886A1 (zh) * | 2020-01-21 | 2021-07-29 | 张晋宇 | 一种药物组合物及其用途 |
| CN113480662B (zh) * | 2021-06-29 | 2022-07-22 | 北京双因生物科技有限公司 | 包含cd40抗体和il-15的融合蛋白及其制备方法和用途 |
| CN116143946B (zh) * | 2022-01-05 | 2025-12-09 | 赛德特生物制药有限公司 | 一种用于免疫治疗的新型融合蛋白、基因、重组载体、宿主细胞及应用 |
| WO2025148750A1 (zh) * | 2024-01-08 | 2025-07-17 | 上药生物治疗（香港）有限公司 | 膜表达il-10及其用途 |
| WO2025221843A1 (en) * | 2024-04-17 | 2025-10-23 | Baylor College Of Medicine | Methods and compositions for suppressing immune cell activation |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
| WO1996011213A1 (en) | 1994-10-07 | 1996-04-18 | Amgen Boulder Inc. | Dimeric il-4 inhibitors |
| AUPN477695A0 (en) | 1995-08-14 | 1995-09-07 | Commonwealth Scientific And Industrial Research Organisation | Gene therapy |
| GB9626029D0 (en) | 1996-12-14 | 1997-01-29 | Univ Leeds | EVH-1 vectors |
| US5998598A (en) | 1997-03-10 | 1999-12-07 | The United States Of America, As Represented By The Department Of Health And Human Services | Immunoadhesins and methods of production and use thereof |
| TR199902878T2 (xx) | 1997-04-18 | 2000-02-21 | Biogen,Inc. | Tip II TGF-Beta Resept�r/�m�noglob�lin sabit b�l�m f�zyon proteinleri. |
| EP1087998A1 (en) | 1998-06-16 | 2001-04-04 | Biogen, Inc. | Variant type ii tgf-beta receptor fusion proteins and methods |
| US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
| US7083950B2 (en) | 1998-09-25 | 2006-08-01 | Regeneron Pharmaceuticals, Inc. | High affinity fusion proteins and therapeutic and diagnostic methods for use |
| JP4944324B2 (ja) | 1999-07-13 | 2012-05-30 | ボルダー バイオテクノロジー， インコーポレイテッド | 免疫グロブリン融合タンパク質 |
| AU778611B2 (en) | 1999-08-09 | 2004-12-16 | Merck Patent Gmbh | Multiple cytokine-antibody complexes |
| US7638604B2 (en) * | 2001-02-23 | 2009-12-29 | Genetics Institute, Llc | Monoclonal antibodies against interleukin-22 |
| US20030125251A1 (en) | 2001-06-21 | 2003-07-03 | Wakefield Lalage M. | Transforming growth factor beta (TGF-beta) antagonist selectively neutralizes "pathological" TGF-beta |
| WO2003066002A2 (en) * | 2002-02-08 | 2003-08-14 | University Of Medicine And Dentistry Of New Jersey | IFN-a/b-INDEPENDENT MECHANISM OF ANTIVIRAL PROTECTION |
| US20070184052A1 (en) | 2003-05-09 | 2007-08-09 | Lin Herbert Y | Soluble tgf-b type III receptor fusion proteins |
| US20090111146A1 (en) | 2003-09-02 | 2009-04-30 | National Institute Of Advanced Industrial Science | Antibody Drug |
| WO2006084327A1 (en) * | 2005-02-09 | 2006-08-17 | Apollo Life Sciences Limited | A molecule and chimeric molecules thereof |
| EP1858923A4 (en) | 2005-02-14 | 2008-10-15 | Apollo Life Sciences Ltd | MOLECULAR AND CHIMERAL MOLECULES FROM IT |
| CN101146825A (zh) * | 2005-02-14 | 2008-03-19 | 阿波罗生命科学有限公司 | 分子及其嵌合分子 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US20090175819A1 (en) * | 2005-11-15 | 2009-07-09 | Apollo Life Sciences Limited | Molecule and chimeric molecules thereof |
| EP3176264B1 (en) | 2007-05-30 | 2018-09-26 | Postech Academy-Industry- Foundation | Immunoglobulin fusion proteins |
| WO2008157367A1 (en) | 2007-06-15 | 2008-12-24 | Genzyme Corporation | Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor |
| EP2293667A4 (en) * | 2008-05-27 | 2012-07-18 | Kyowa Hakko Kirin Co Ltd | INTERLEUKIN 10-RECEPTOR (IL-10R) ANTIBODY AND USE PROCESS |
| US20110177070A1 (en) | 2008-07-02 | 2011-07-21 | Emergent Product Development Seatlle, LLC | TGF-Beta Antagonist Multi-Target Binding Proteins |
| EP2326670A4 (en) | 2008-09-17 | 2014-04-16 | Nat Res Council Canada | HETERO MULTIVALENT BINDING AGENT FOR ELEMENTS OF THE TGF-BETA SUPERFAMILY |
| PT2403951E (pt) | 2009-03-02 | 2016-01-29 | Univ California | Mutantes de adenovírus e1a e e1b de tumores |
| IL300733B1 (en) | 2010-03-05 | 2025-10-01 | Univ Johns Hopkins | Compositions and methods for antibodies and fusion proteins targeted for immune modulation |
| EP4219536A3 (en) | 2012-04-30 | 2023-08-23 | Biocon Limited | Targeted/immunomodulatory fusion proteins and methods for making same |
| PT2970512T (pt) | 2013-03-12 | 2019-01-17 | Biocon Ltd | Proteínas de fusão imunomoduladoras e métodos para produção das mesmas |
| CN105658672A (zh) | 2013-08-22 | 2016-06-08 | 阿塞勒隆制药公司 | TGF-β受体II型变体及其用途 |
| EP4005585B1 (en) | 2013-11-21 | 2024-03-27 | The Brigham & Women's Hospital, Inc. | Compositions and methods for treating right ventricular hypertrophy |
| SG11201606577YA (en) | 2014-02-10 | 2016-09-29 | Merck Patent Gmbh | TARGETED TGFβ INHIBITION |
| US20160175458A1 (en) | 2014-12-19 | 2016-06-23 | Alkermes, Inc. | Single chain fc fusion proteins |
| CA2979973A1 (en) * | 2015-04-29 | 2016-11-03 | Mediolanum Farmaceutici S.P.A. | A soluble chimeric interleukin-10 receptor and therapeutic use thereof |
| EP3344660B1 (en) | 2015-08-31 | 2025-03-05 | National Research Council of Canada | Tgf-beta-receptor ectodomain fusion molecules and uses thereof |
| EP3519442A4 (en) | 2016-09-27 | 2020-06-17 | EpicentRx, Inc. | Immunomodulatory fusion proteins |
| US10232053B2 (en) * | 2016-12-30 | 2019-03-19 | Trieza Therapeutics, Inc. | Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer |
-
2018
- 2018-09-27 IL IL273626A patent/IL273626B2/en unknown
- 2018-09-27 KR KR1020207011933A patent/KR102757384B1/ko active Active
- 2018-09-27 EP EP18862997.6A patent/EP3688037A4/en active Pending
- 2018-09-27 EA EA202090838A patent/EA202090838A1/ru unknown
- 2018-09-27 WO PCT/US2018/053197 patent/WO2019067770A1/en not_active Ceased
- 2018-09-27 CA CA3077223A patent/CA3077223A1/en active Pending
- 2018-09-27 SG SG11202002826VA patent/SG11202002826VA/en unknown
- 2018-09-27 US US16/651,079 patent/US11834492B2/en active Active
- 2018-09-27 AU AU2018338612A patent/AU2018338612A1/en not_active Abandoned
- 2018-09-27 MX MX2020003672A patent/MX2020003672A/es unknown
- 2018-09-27 CN CN201880075263.5A patent/CN111511769B/zh active Active
- 2018-09-27 CN CN202410618028.5A patent/CN118652350A/zh active Pending
- 2018-09-27 JP JP2020517588A patent/JP2020536518A/ja not_active Withdrawn
- 2018-09-27 BR BR112020006115-8A patent/BR112020006115A2/pt unknown
-
2023
- 2023-05-16 JP JP2023081001A patent/JP7702445B2/ja active Active
- 2023-10-25 US US18/494,508 patent/US20240052016A1/en active Pending
-
2025
- 2025-10-09 AU AU2025248681A patent/AU2025248681A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020536518A5 (enExample) | ||
| JP2023096044A5 (enExample) | ||
| JP7253020B2 (ja) | キメラ抗原受容体およびその使用 | |
| ES2207278T3 (es) | Heterominicuerpos. | |
| ES2833162T5 (es) | Receptor de antígeno quimérico y su uso | |
| JP6613304B2 (ja) | 抗ｃｄ２７６抗体（ｂ７ｈ３） | |
| CA2902830C (en) | Fusion immunomodulatory proteins and methods for making same | |
| JP2019531728A5 (enExample) | ||
| IL273626B1 (en) | Fusion proteins and immune modulators | |
| ES2948717T3 (es) | Nueva proteína de fusión específica para CD137 y PD-L1 | |
| MX2011009810A (es) | Composiciones y metodos para usar proteinas de union multiespecificas que comprenden una combinacion anticuerporeceptor. | |
| CN118955716A (zh) | 结合cd137的单结构域抗体 | |
| MX2023005420A (es) | Anticuerpo bcma humanizado y linfocitos t car-bcma. | |
| RU2017130985A (ru) | Фармацевтическая композиция и способ снижения ингибирующего эффекта pd-l1 на т-клетки человека | |
| JP2016534717A5 (enExample) | ||
| JP2018525006A5 (enExample) | ||
| JPWO2019169290A5 (enExample) | ||
| WO2014160627A1 (en) | Anti-cd276 polypeptides, proteins, and chimeric antigen receptors | |
| JP2017536091A (ja) | 多価メディトープ、メディトープ結合性抗体およびそれらの使用 | |
| JP2022542543A (ja) | 抗ｄｌｌ３キメラ抗原受容体及びその使用 | |
| JP2022528030A (ja) | 多機能性融合タンパク質及びその使用 | |
| WO2015164627A1 (en) | Chimeric antigen receptors specific to avb6 integrin and methods of use thereof to treat cancer | |
| US20240270812A1 (en) | Tmigd2 and its derivatives as blockers or binders of cancer-expressed hhla2 for immunotherapies | |
| BR112019017713A2 (pt) | proteínas quiméricas à base de csf1r | |
| JP2025161810A (ja) | Ｉｌ－１スーパーファミリーのサイトカインの空間時間的に制限された活性が武装化された免疫応答性細胞 |